Core Insights - The company is optimistic about its growth trajectory, projecting at least 18% top-line growth for 2026, driven by early-stage market penetration in various areas including trauma extremities and elective procedures [2] - A recent capital raise of $142 million has strengthened the company's balance sheet, allowing for debt elimination and improved profit-and-loss profile [3] - The company has experienced over 20% top-line growth in the last two quarters of the previous year, indicating broad-based commercial strength [4] Financial Performance - The company expects a $17 million loss in the first quarter, but the new funds are anticipated to enhance cash generation moving forward [3] - Initial sales of the biologic-labeled AVANCE are expected to begin in Q2, although initial costs may pressure gross margins [9] Market Dynamics - The recent BLA approval for AVANCE is seen as a significant operational milestone, allowing the company to streamline its quality systems and improve operational efficiencies [6][9] - Changes in reimbursement dynamics, particularly for outpatient settings, are expected to positively impact the company's operations, although awareness and negotiations with payers will take time [8] Strategic Focus - The company is focusing on underpenetrated markets, particularly in the breast vertical, and is exploring early work in prostate procedures [10] - Management emphasized the importance of demonstrating reproducible outcomes before significant investments in broader market development [10] Product Portfolio - The core product offerings include the Avance® Nerve Graft and Axoguard® Nerve Connector and Protector devices, which aim to restore nerve function and improve patient outcomes [11][12]

Core Insights - AxoGen reported a significant financial inflection point, driven by the FDA approval of the Avance biologics license application (BLA) and accelerating adoption of its nerve repair algorithm [5][7] Financial Performance - Fourth-quarter revenue reached $59.9 million, marking a 21.3% increase year-over-year, while full-year revenue rose 20.2% to $225.2 million [4][8] - Gross margin for the fourth quarter was 74.1%, down from 76.1% a year earlier, and full-year gross margin was 74.3%, compared to 75.8% in 2024 [2] - The company reported a fourth-quarter net loss of $13.2 million, or $0.28 per share, compared to a net income of $0.5 million, or $0.01 per share, in the prior-year quarter [9] Strategic Initiatives - Management emphasized six strategic priorities for market development and commercial expansion across various medical fields, including extremities and breast [12] - The company plans to expand its commercial organization, with new hires expected to reach independence within six to nine months [15] Market Dynamics - The FDA BLA approval for Avance is expected to enhance payer coverage, with commercial coverage projected to exceed 65% after 2025 [7][21] - Approximately 19.8 million additional lives gained coverage in 2025, indicating a positive trend in reimbursement dynamics [21] 2026 Outlook - AxoGen guided for at least 18% revenue growth in 2026, implying revenue of at least $265.7 million, with a gross margin target of 74% to 76% [6][24] - The company anticipates being free-cash-flow positive for the full year of 2026, despite expected higher cash burn in the first quarter [24]

Core Insights - Axogen, Inc. reported significant financial and operational achievements in 2025, including FDA approval for Avance, which is the only implantable biologic for peripheral nerve discontinuities, positioning the company for future growth [3][6]. Fourth Quarter Financial Results - Fourth quarter 2025 revenue reached $59.9 million, marking a 21.3% increase from the same quarter in 2024, but a slight decrease of 0.3% compared to the third quarter of 2025 [5]. - The gross margin for the fourth quarter was 74.1%, down from 76.1% in Q4 2024 and 76.6% in Q3 2025, influenced by one-time costs of approximately $1.9 million related to the FDA approval [5]. - The net loss for Q4 2025 was $13.2 million, or $0.28 per share, compared to a net income of $0.5 million, or $0.01 per share, in Q4 2024 [5]. - Adjusted net income for Q4 2025 remained at $3.5 million, or $0.07 per share, consistent with Q4 2024 [5]. - Adjusted EBITDA for Q4 2025 was $6.5 million, slightly down from $6.7 million in Q4 2024 [5]. - Cash and cash equivalents increased by $5.7 million during Q4 2025 [5]. Full-Year Financial Results - Full-year 2025 revenue totaled $225.2 million, a 20.2% increase from $187.3 million in 2024 [6]. - The gross margin for the full year was 74.3%, down from 75.8% in 2024, also reflecting one-time costs related to FDA approval [6]. - The net loss for 2025 was $15.7 million, or $0.34 per share, compared to a net loss of $10.0 million, or $0.23 per share, in 2024 [6]. - Adjusted net income for 2025 was $14.4 million, or $0.29 per share, up from $5.9 million, or $0.13 per share, in 2024 [6]. - Adjusted EBITDA for the full year was $27.9 million, compared to $19.8 million in 2024 [6]. - As of December 31, 2025, cash and cash equivalents, restricted cash, and investments totaled $45.5 million, an increase of $6.0 million from $39.5 million at the end of 2024 [6]. Business Highlights - The company experienced broad-based revenue growth in 2025, with double-digit growth across all markets, including Extremities, Oral Maxillofacial & Head and Neck, and Breast [13]. - Expanded coverage and reimbursement for peripheral nerve repair increased the number of newly covered lives to approximately 19.8 million, raising commercial payer coverage to over 65% [13]. - The FDA approved the BLA for Avance on December 3, 2025, and CMS created a new Level 3 Nerve Procedure Code effective January 1, 2026, increasing Avance facility reimbursement by 40% year-over-year [13]. - Axogen closed an upsized public offering on January 23, 2026, selling 4.6 million shares and yielding net proceeds of $133.3 million, with a portion used to repay debt [13]. 2026 Financial Guidance - The company expects at least 18% revenue growth in 2026, projecting full-year revenue of $265.7 million, with gross margin anticipated to be between 74% and 76% [8].

Investment Activity - Principal Financial Group Inc. increased its holdings in AxoGen, Inc. by 69.7% during the 3rd quarter, acquiring an additional 21,002 shares, bringing its total to 51,130 shares valued at approximately $912,000 [2] - Other large investors also modified their holdings, with Royal Bank of Canada increasing its stake by 14.2% to 38,043 shares worth $704,000, and AQR Capital Management raising its holdings by 45.3% to 23,917 shares valued at $442,000 [3] Stock Performance - AxoGen stock opened at $35.25, with a market cap of $1.63 billion, a P/E ratio of -705.00, and a beta of 1.00 [4] - The company has a current ratio of 4.09, a quick ratio of 2.64, and a debt-to-equity ratio of 0.54, with a 12-month low of $9.22 and a high of $36.00 [4] Insider Transactions - Director Kathy Johnson Weiler sold 46,653 shares at an average price of $29.55, totaling $1,378,596.15, while Director John Johnson sold 23,693 shares at an average price of $31.24, totaling $740,169.32, representing a 64.32% decrease in his ownership [5] - In the last quarter, insiders sold 301,680 shares worth $9,174,052, with insiders owning 2.78% of the company's stock [5] Analyst Ratings - AxoGen received several positive analyst ratings, with Wall Street Zen upgrading it to a "strong-buy" and Lake Street Capital raising its price target from $30.00 to $40.00 [6] - The consensus rating for AxoGen is "Moderate Buy" with an average target price of $35.75, supported by nine analysts rating it as a Buy and one as a Sell [6] Company Overview - AxoGen, Inc. is a Florida-based medical technology company focused on developing surgical solutions for peripheral nerve damage, aiming to restore nerve function and improve patient outcomes [8] - The company's core products include the Avance® Nerve Graft and the Axoguard® Nerve Connector and Protector devices, which provide alternatives to traditional nerve autografts [9]

Core Viewpoint - Axogen, Inc. is set to release its financial results for Q4 and the full year 2025 on February 24, 2026, followed by a conference call for the investment community [1]. Company Overview - Axogen, Inc. is a leader in developing and marketing surgical solutions aimed at restoring peripheral nerve function, with a mission to establish nerve repair as the standard of care [3]. - The company focuses on the science, development, and commercialization of technologies for peripheral nerve repair, collaborating with surgeons and healthcare providers globally [3]. Product Portfolio - Axogen's product offerings include: - Avance® (acellular nerve allograft-arwx) - Avance® Nerve Graft - Axoguard Nerve Connector® - Axoguard Nerve Protector® - Axoguard HA+ Nerve Protector™ - Axoguard Nerve Cap® - Avive+ Soft Tissue Matrix™ [4].

Core Viewpoint - Axogen, Inc. has announced an upsized public offering of 4,000,000 shares of common stock priced at $31.00 per share, aiming to raise approximately $124 million before expenses [1][3]. Group 1: Offering Details - The public offering is set to close on January 23, 2026, pending customary closing conditions [2]. - Wells Fargo Securities and Mizuho are the lead book-running managers, with Canaccord Genuity and Raymond James serving as co-managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for early payoff and termination of a term loan facility with Oberland Capital, working capital, capital expenditures, and other general corporate purposes [3]. Group 3: Regulatory Information - The offering is made under an automatic shelf registration statement on Form S-3ASR, effective upon filing with the SEC on January 21, 2026 [4]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available for free on their website [4]. Group 4: Company Overview - Axogen focuses on the development and commercialization of technologies for peripheral nerve repair, aiming to establish nerve repair as the standard of care [6]. - The company's product portfolio includes various nerve repair solutions such as Avance® and Axoguard® products [7].

Core Viewpoint - Axogen, Inc. plans to offer and sell $85.0 million of its common stock in a proposed underwritten public offering, with an additional option for underwriters to purchase up to $12.75 million more [1][2] Group 1: Offering Details - The proposed offering is subject to market conditions and other factors, with no assurance on the completion or terms of the offering [1] - Wells Fargo Securities and Mizuho are the lead book-running managers, while Canaccord Genuity and Raymond James are co-managers for the offering [2] - The offering is made under an automatic shelf registration statement that became effective upon filing with the SEC on January 21, 2026 [3] Group 2: Use of Proceeds - Axogen intends to use the net proceeds from the offering for early payoff and termination of its term loan facility with Oberland Capital, working capital, capital expenditures, and other general corporate purposes [2] Group 3: Company Overview - Axogen focuses on the science, development, and commercialization of technologies for peripheral nerve repair, aiming to make nerve repair the expected standard of care [5] - The company's product portfolio includes various nerve repair solutions such as Avance® nerve grafts and Axoguard® products [6]

Financial Performance - Q3 2025 revenue increased to $60.1 million, a 23.5% year-over-year growth[11] - Net income for Q3 2025 was $0.7 million, compared to a loss of $1.9 million in Q3 2024[22] - Adjusted EBITDA for Q3 2025 was $9.2 million, with an Adjusted EBITDA margin of 15.4%[22] - Operational cash increased by $3.9 million, reaching $39.8 million as of September 30, 2025[24] Business Growth & Development - High Potential (HiPo) accounts contributed approximately 64% of year-over-year revenue growth[11] - HiPo accounts showed a 19% year-over-year increase in average account productivity[11] - The company trained 62 surgeon pairs in Breast procedures YTD, with 281 procedures performed in Q3, a 20% year-over-year increase[11] - The company trained 57 surgeons in OMF/H&N procedures YTD, exceeding the target of 45[11] - Approximately 1.1 million estimated additional covered lives were added in Q3, with approximately 18.1 million new lives YTD[13] Guidance - The company is raising guidance for the full year 2025, projecting revenue growth of at least 19%, or $222.8 million[26]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Axogen, Inc. and its officers or directors [1] Group 1: Company Developments - On August 25, 2025, Axogen announced that the FDA extended the PDUFA goal date for its Biologics License Application for Avance® Nerve Graft by three months to December 5, 2025 [3] - Following this announcement, Axogen's stock price decreased by $1.47 per share, or 9.04%, closing at $14.79 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is representing investors in investigating claims against Axogen for possible securities fraud or other unlawful business practices [1] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [4]